Business
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
Acquisition Expands The Company’s Commercial Portfolio With An Established U.S. Marketed Product Company Remains Dedicated To Growth Within Neurology Through
About this update from Catalyst Pharmaceuticals, Inc.
[{"type":"text","content":"Acquisition Expands The Company’s Commercial Portfolio With An Established U.S. Marketed Product Company Remains Dedicated To Growth Within Neurology Through Continued Active Business Development Strategy Into Synergistic Adjacencies Transaction Includes Exclusive Period To Evaluate And Negotiate To Acquire A Rare Epilepsy Compound In Development Acquisition Expected to be EBITDA and EPS Accretive in 2023 CORAL GABLES, Fla., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (\"Catalyst\") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it has entered into a definitive agreement with Eisai Co., Ltd, (“Eisai”) under which Catalyst will acquire the U.S. rights for FYCOMPA® (perampanel) CIII and an exclusive option period to review, evaluate and negotiate to acquire a rare epilepsy asset currently in Eisai’s pipeline. The acquisition adds a highly complementary and established marketed product in neurology that diversifies Catalyst’s commercial product portfolio and paves the way for further expansion into other rare neurological diseases that address critical unmet medical needs. Catalyst has been advised that Eisai's U.S. FYCOMPA net revenues for the 2022 fiscal year ending March 31, 2023, will approximate $136 million. Catalyst expects the acquisition to be accretive upon closing to Catalyst's earnings in 2023 before interest, taxes, depreciation, and amortization (“EBITDA”) and to EPS. “This agreement broadens our commercial portfolio and provides an option to add a late-stage rare neurology asset that would further build upon our core competencies with differentiated medicines that treat rare neurological and epileptic disorders,” said Patrick J. McEnany, Chairman and CEO of Catalyst. “Over the course of this year, our team has followed a focused and diligent process in pursuit of value-added transaction opportunities, and we are pleased to have delivered on this objective which we believe serves as a strategic catalyst for sustained future growth to our current strong revenues from FIRDAPSE®. Our portfolio expansion efforts and business development pipeline of prospects both continue to remain robust, with several additional opportunities under active due diligence th...